# Honasa Consumer | BUY

## Strong quarter; improving outlook - Upgrade to BUY

Honasa's 2QFY26 earnings print was tad better on revenue front but once again profitability was significantly ahead of exceptions – LTL sales growth was 22.5% (UVG of 16.7%). Mamaearth primary sales were back in green (low-single-digit growth if we add back inventory impact in the base quarter), while young brands sustained momentum growing at 20%. Initiatives around reviving growth in Mamaearth are showing promising results and management commentary was optimistic in terms of accelerating growth to double digits by 4QFY26E. Further on profitability, the pace of margin expansion has been much ahead of our expectations for past few quarters (led by improved mix and operating leverage), which should sustain led by improving growth in Mamaearth, scale up in premium brands and marketing efficiencies. Working capital remains negative. We raise our FY26-28E by 2-5%. Given recent correction in stock and improving outlook, we upgrade our rating from ADD to BUY with revised DCF based TP of INR 330 (earlier INR 325).

- Revenue performance broadly inline: Consol. revenue grew 16.5% YoY to INR 5.4bn (inline with our and street estimates), driven by robust UVG of 16.7% YoY. During the quarter, revenue recognition was lower due to change in settlement terms by flipkart (impact on revenue of INR 280mn as logistics & fulfilment costs are now netted off from revenue); however, there is no corresponding impact on profitability. On LFL basis, revenue growth stood at 22.5% YoY. Focus categories (contributing to 75% of total revenue vs. 70% last year) continued on its double-digit growth trajectory across channels (MT/e-commerce sustained 20%+ growth, GT secondary sales: double-digit growth). Overall distribution reach was up 20% YoY to c.250k+ outlets with direct distributor now contributing to 79% of revenue vs. 33% in 2QFY24. We are factoring low-double-digit sales CAGR over FY26-28E led by improving growth in Mamaearth and c.20% sales growth in young brands
- Mamaearth growth turns positive; momentum for younger brands sustains: Flagship brand Mamaearth's strategic pivot continues to show signs of improvement with sustained double-digit growth in e-commerce/MT and single-digit secondary sales growth in GT (primary sales were also positive). Adjusting for inventory impact in base quarter, Mamaearth sales grew in low single digits. Younger brands (The Derma Co., Aqualogica, Bblunt, Dr. Sheth's and Staze) grew 20% YoY. Further, management tapped into two new growth spaces a) entry into prestige night-focused skin care with new brand Lumineve and b) prestige oral care focused on teeth whitening and oral wellness via investment in FANG (25% stake for INR 100mn).
- Margin delivery positively surprises (ahead of our forecasts and mgmt. guidance) yet again: Gross margin improved by 172bps YoY to 70.5% (JMFe: 70%) led by sourcing efficiencies and better product mix (younger brands having higher margins). Staff cost grew 16.3% YoY, while A&P spends declined 1.6% YoY and other expenses declined 19.4% (shifting of cost to revenue by flipkart and scale efficiency). Resultant EBITDA margin trajectory improved to 8.9% vs. 7.7% in 1Q and 3.3% in FY25, was much better vs. our expectations of 7.3%. Reported PAT of INR 392mn was 8% ahead of our expectation, driven by better-than-expected EBITDA performance. Going forward, management expects to sustain EBITDA margin trajectory at current levels of 1H aided by better mix and operating leverage (especially on marketing spends). We are building in EBITDA margin of c.8% for FY26E.



Mehul Desai mehul.desai@jmfl.com | Tel: (91 22) 66303065

Gaurav Jogani

gaurav.jogani@jmfl.com | Tel: (91 22) 66303085

Pooja Kubadia

pooja.kubadia@jmfl.com | Tel: (91 22) 66303074

Rajat Gupta

rajat.gupta@jmfl.com | Tel: (91 22) 66303077

Recommendation and Price Target	
Current Reco.	BUY
Previous Reco.	ADD
Current Price Target (12M)	330
Upside/(Downside)	17.0%
Previous Price Target	325
Change	1.5%

Key Data – HONASA IN	
Current Market Price	INR282
Market cap (bn)	INR91.8/US\$1.0
Free Float	47%
Shares in issue (mn)	325.2
Diluted share (mn)	325.2
3-mon avg daily val (mn)	INR229.0/US\$2.6
52-week range	388/190
Sensex/Nifty	84,467/25,876
INR/US\$	88.6

Price Performa	ance		
%	1M	6M	12M
Absolute	-3.4	13.7	-24.6
Relative*	-5.6	11.0	-29.8

\* To the BSE Sensex

Financial Summary					(INR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Sales	19,199	20,669	23,222	26,314	29,904
Sales Growth (%)	28.6	7.7	12.3	13.3	13.6
EBITDA	1,371	685	1,847	2,406	3,100
EBITDA Margin (%)	7.1	3.3	8.0	9.1	10.4
Adjusted Net Profit	1,118	727	1,541	2,017	2,628
Diluted EPS (INR)	3.4	2.2	4.7	6.2	8.1
Diluted EPS Growth (%)	295.3	-35.2	112.0	30.9	30.3
ROIC (%)	26.7	4.4	18.6	26.6	38.2
ROE (%)	13.1	6.4	12.5	14.9	17.8
P/E (x)	81.8	126.2	59.5	45.5	34.9
P/B (x)	8.3	7.8	7.1	6.5	5.9
EV/EBITDA (x)	61.2	124.4	45.5	34.3	26.1
Dividend Yield (%)	0.0	0.0	0.5	0.9	1.4

Source: Company data, JM Financial. Note: Valuations as of 12/Nov/2025

JM Financial Research is also available on: Bloomberg - JMFR <GO>, FactSet, LSEG and S&P Capital IQ.

Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification.

## Concall Highlights

■ Evolving category in India's BPC market: India's premium oral care market is set to reach \$700mn by 2030 drievn by demand for whitening and advanced benefits. Management expects huge headroom for premiumisation in this category led by rising health and aesthetic consciousness and insurgent brands gaining market share. The company is ready to tap into this opportunity through inorganic investment in FANG.

#### Operational performance

- Management highlighted that on like-for-like basis revenue growth stood at 22.4%. During the quarter there was a change in financial reporting on account of change in settlement from its key customer Flipkart. The company operates as a marketplace seller and previously, flipkart provided an invoice for logistics and fulfilment costs (which was a part of other overheads). However, flipkart has now changed its settlement policy and is reducing the logistics and fulfilment costs from revenue, which resulted into lower revenue recognition for the company. Overall financial impact for the quarter stood at INR 280mn resulting into sales growth of 16.5% YoY. From net contribution margin perspective, there will be no impact.
- With respect to strategic change in playbook, focus categories continue to grow well across channels including general trade and now contributes to 75% of total revenue. Management targets to improve this contribution to c.85%.
- Gross margin profile has seen a consistent improvement and is now averaging at the 71% mark. Levers for improvement are a) performance efficiencies and b) favourable product mix. This will further improve after entry into the prestige categories.

#### Mamaearth

- Mamaearth is showing positive results on sequential basis and has turned green across channels. Previously, e-commerce and modern trade channels saw good growth profiles; however, now general trade trajectory is also improving with single-digit growth in secondary sales. Management highlighted that the primary sales in general trade has also turned positive.
- Moving forward, management endeavors to continue improving on sequential basis and report high-single-digit growth in 3Q and double-digit growth in 4Q on LFL basis. Taking into account the base correction due to flipkart, the brand is likely to grow in single digits.
- At the moment, Mamaearth's revised playbook focuses on driving growth in the six core categories. Once it reaches a scale of INR 1,500-2,000 crores with significant improvement in profitability, management will then focus on adding a 7<sup>th</sup> category to its focus area. The next big category would be body products such as body lotion, body wash etc.

## Younger brands

- Young brands continue on a strong growth trajectory with 20% growth driven by the strategy of building plus one category out of their core categories/partitions.
- The Derma Co. which is the second largest brand is reaching newer heights and clocked an ARR of INR 750 crores in net sales with high-single-digit EBITDA margin. As per Euromonitor, it is the No.1 sunscreen brand in India for CY24. It is now looking to build strength in other focus categories such as moisturiser and shampoo categories which will aid to reach the INR 1,000 crores mark over the next 1-2 years.
- Future of TDC: Management highlighted that focus will remain to drive growth in the existing
  four categories which still has a lot of growth potential. Thereafter, management will focus
  on the other two categories i.e. moisturiser and hair along with offline expansion. At present,
  the offline sales for TDC stands at INR 100 crores.
- Staze is progressing well and has tripled on YoY basis.

#### New growth engines

New brand: The company introduced Lumineve - a prestige night-focused skin care brand rooted in global dermatologist expertise, powered by exclusive ingredient technologies. This is launched in exclusive partnership with Nykaa. It will cater to the prestige skin care market which is expected to be \$4bn by 2030. The brand is priced 2.5x higher vs. current product categories.

Inorganic opportunity: The management is witnessing a rise in oral beauty over the next decade and is looking to tap this opportunity by investing behind brands at an early stage. Focus remains to play within 2-3 partitions in this category and build that over the next decade. The company announced its investment in FANG (portfolio inline with management's strategic vision) which is a prestige oral care brand focused on teeth whitening and everyday oral wellness. The company acquired 25% stake for INR 100mn (5.7x on net sales ARR of INR 70mn as on Sep'25).

#### Distribution and channel expansion

- Apart from Mamaearth, GT distribution has been continuous area of focus and management continues to sequential improvement in secondary sales 35% YoY growth in direct outlet billing.
- From direct distribution perspective, the company improved its contribution from direct distributor to 79% of GT primary sales vs. 33% in 2QFY24.
- Total FMCG retail outlet reach grew by 20% YoY to c.250k outlets as on Sep'25.
- E-commerce is the fastest growing channel accounting for 10% of total revenues.
- Project Neev: The company is in process of transitioning from a three-layer distribution system to two-layer in the top 100 cities, out of this 85% has been achieved and the balance 15% will be completed by end of FY26.

#### Guidance

- Management has guided to maintain EBITDA margins at current levels (i.e 8.2% in 1H) for FY26, which is an upgrade vs. previous guidance on 7%.
- Management expects to see increased scale-led efficiency across marketing investments as younger brands continue to scale. Management reiterates its target to improve margins by 50-100bps on YoY basis.

### Other highlights

- 80% business is now coming from direct distribution.
- Re-innovation leading to superior product upgrades continues with the launch of TDC 10% vitamin C serum and Aqualogica India's first in-vivo tested sunscreen with anti-pollution factor.
- Premiumization remains strong with collaboration-driven innovation and entry into prestige segment with newer launches and brand.

Exhibit 1. 2QFY26 result snapshot: Revenue largely inline; better-than- expected gross margins alongwith scale leverage drives earnings beat Consolidated financials (INR mn) 2QFY26 2QFY25 YoY growth 2QFY26E % Var 1HFY26 1HFY25 YoY growth 4,618 16.5% 5,357 11,333 Revenue from operations 5,381 0.4% 10,159 11.6% **Gross Profit** 3,793 3,176 19.4% 3,750 1.1% 8,031 7,147 12.4% Gross Profit Margin % 70.5% 68.8% 172 bps 70.0% 49 bps 70.9% 70.3% 52 bps Staff Cost 598 515 16.3% 595 0.6% 1,202 1,009 19.2% A&P 1,800 1,830 -1.6% 1,821 -1.2% 3,860 3,830 0.8% 1,139 -5.5% Other Expenses 918 -19.4% 943 -2.6% 2,035 2,154 EBITDA 476 -307 NM 391 21.8% 934 154 506.2% EBITDA margin % 8.9% -6.6% NM 7.3% 155 bps 8.2% 1.5% 673 bps Depreciation 117 106 11.1% 112 4.3% 226 200 12.9% EBIT 359 -413 NM 279 28.9% 709 NM -46 Interest Expense 33 31 5.2% 33 -0.1% 66 62 6.8% Financial Other Income 201 200 0.6% 240 -16.1% 440 387 13.6% PBT NM 486 8.6% 1,083 286.6% 527 -244 280 135 -58 NM 122 10.5% 278 63 338.3% Taxes Reported Net Profit 392 -186 NM 363 8.0% 806 217 271.5%

Source: Company, JM Financial

Exhibit 2. Quarterly financial performance – on consolidated basis										
INR mn	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	
Volume Growth (%)	27.0%	35.0%	27.5%	25.2%	7.1%	1.5%	21.2%	10.5%	16.7%	
Sales	4,961	4,882	4,711	5,541	4,618	5,175	5,336	5,953	5,381	
YoY	21%	28%	21%	19%	-7%	6%	13%	7%	17%*	
Gross Profit	3,446	3,351	3,296	3,970	3,176	3,620	3,774	4,238	3793	
Staff cost	371	442	448	494	515	518	478	604	598	
A&P spends	1,740	1,660	1,600	2,000	1,830	1,770	1,840	2,060	1,800	
Other expenses	933	904	917	1,015	1,139	1,071	1,186	1,117	918	
EBITDA	402	345	331	461	(307)	261	270	458	476	
YoY	53%	192%	NM	57%	-176%	-24%	-19%	-1%	NM	
Depreciation	63	81	98	94	106	126	124	108	117	
Interest	18	26	31	30	31	33	32	33	33	
Other income	71	110	190	187	200	192	208	239	201	
PBT	392	347	393	524	(244)	294	322	556	527	
YoY	69%	226%	NM	54%	-162%	-15%	-18%	6%	NM	
Tax	98	88	88	121	(58)	34	72	143	135	
PAT	294	259	305	403	(186)	260	250	413	392	
YoY	73%	174%	NM	55%	-163%	0%	-18%	3%	NM	
% to sales	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	
Gross margin	69.5%	68.6%	70.0%	71.7%	68.8%	70.0%	70.7%	71.2%	70.5%*	
Staff cost	7.5%	9.0%	9.5%	8.9%	11.1%	10.0%	8.9%	10.1%	11.1%	
A&P spends	35.1%	34.0%	34.0%	36.1%	39.6%	34.2%	34.5%	34.6%	33.5%	
Other expenses	18.8%	18.5%	19.5%	18.3%	24.7%	20.7%	22.2%	18.8%	17.1%	
EBITDA margin	8.1%	7.1%	7.0%	8.3%	-6.6%	5.0%	5.1%	7.7%	8.9%*	

Source: Company, JM Financial.

<sup>\*</sup>LFL sales growth: 22.5%, LFL gross margin: 71.9% and LFL EBITDA margin: 8.4%.

# Exhibit 3. Honasa's avg. EV/sales Band



Source: Bloomberg, Company, JM Financial

Exhibit 4. Our 12-month DCF based price target works out to INR 330/share																
(INR mn)	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E	FY28E	FY29E	FY30E	FY31E	FY32E	FY33E	FY34E	FY35E
Revenue	1,098	4,600	9,435	14,927	19,199	20,669	23,222	26,314	29,904	34,009	38,773	43,554	48,525	53,394	58,823	64,881
yoy growth		319.0%	105.1%	58.2%	28.6%	7.7%	12.3%	13.3%	13.6%	13.7%	14.0%	12.3%	11.4%	10.0%	10.2%	10.3%
EBITDA	-78	272	115	228	1,371	685	1,847	2,406	3,100	3,918	4,813	5,780	6,885	8,083	9,117	10,280
EBITDA margin %	-7.1%	5.9%	1.2%	1.5%	7.1%	3.3%	8.0%	9.1%	10.4%	11.5%	12.4%	13.3%	14.2%	15.1%	15.5%	15.8%
EBIT	-85	255	46	-22	1,065	235	1,338	1,815	2,432	3,153	3,944	4,802	5,793	6,870	7,772	8,793
EBIT margin %	-7.7%	5.5%	0.5%	-0.1%	5.5%	1.1%	5.8%	6.9%	8.1%	9.3%	10.2%	11.0%	11.9%	12.9%	13.2%	13.6%
Tax Rate	0.0%	-0.6%	35.6%	-7.0%	24.9%	18.9%	25.3%	25.3%	25.3%	25.3%	25.3%	25.3%	25.3%	25.3%	25.3%	25.3%
NOPAT	-85	256	29	-24	800	191	999	1,356	1,816	2,355	2,946	3,587	4,328	5,132	5,806	6,568
Depreciation	6	17	69	250	306	450	509	591	669	766	869	978	1,092	1,213	1,344	1,487
Capex	-4	-10	-1,176	-285	-123	-170	-557	-526	-598	-646	-698	-740	-776	-854	-941	-1,038
Net working capital investment	-42	-1	2	-1,187	-331	-2,505	-108	247	76	504	-544	311	-504	-517	-513	-574
Free Cash Flow	-125	262	-1,075	-1,246	651	-2,034	843	1,668	1,963	2,979	2,573	4,135	4,140	4,974	5,696	6,443
YoY Growth - %								97.8%	17.7%	51.8%	-13.6%	60.7%	0.1%	20.2%	14.5%	13.1%
Discounting Factor							1.00	0.97	0.88	0.79	0.71	0.64	0.58	0.52	0.47	0.42
Present Value of FCF							843	1,625	1,723	2,356	1,833	2,654	2,393	2,591	2,673	2,724
Fade period forecast	FY36E	FY37E	FY38E	FY39E	FY40E	FY41E	FY42E	FY43E	FY44E	FY45E F	Y36-45 CA	GR				

Fade period forecast	FY36E	FY37E	FY38E	FY39E	FY40E	FY41E	FY42E	FY43E	FY44E	FY45E FY	/36-45 CAGR	
FCF	7,249	8,111	9,026	9,988	10,993	12,031	13,094	14,171	15,249	16,317	9.4%	
Discounting Factor	0.38	0.34	0.31	0.28	0.25	0.23	0.20	0.18	0.17	0.15		
Present Value of FCF	2,761	2,783	2,790	2,782	2,758	2,719	2,666	2,600	2,520	2,429		

12M Forward Equity Valuation	
PV of Cash Flow - Explicit Period	20,571
PV of Cash Flow - Fade Period	26,808
PV of Terminal Value	51,503
Enterprise Value	98,881
Debt	0
Cash	7,608
Net Debt	-7,608
Equity value	106,488
No of Shares (mn)	325
Target price (INR per share)	330
6 6 145 11	

Source: Company, JM Financial

Exhibit 5. Revision in estimates										
INR mn		Revised			Earlier		Change (%)			
INK MN	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	
Sales	23,222	26,314	29,904	23,332	26,684	30,414	-0.5%	-1.4%	-1.7%	
EBITDA	1,847	2,406	3,100	1,636	2,281	3,055	12.9%	5.5%	1.5%	
PAT	1,541	2,017	2,628	1,474	1,990	2,581	4.5%	1.4%	1.8%	
EPS	4.7	6.2	8.1	4.5	6.1	7.9	4.5%	1.4%	1.8%	

Source: Company, JM Financial

# Financial Tables (Consolidated)

Income Statement				(II	NR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Sales	19,199	20,669	23,222	26,314	29,904
Sales Growth	28.6%	7.7%	12.3%	13.3%	13.6%
Other Operating Income	0	0	0	0	0
Total Revenue	19,199	20,669	23,222	26,314	29,904
Cost of Goods Sold/Op. Exp	5,807	6,129	6,571	7,441	8,450
Personnel Cost	1,706	2,004	2,348	2,587	2,863
Other Expenses	10,315	11,851	12,456	13,879	15,490
EBITDA	1,371	685	1,847	2,406	3,100
EBITDA Margin	7.1%	3.3%	8.0%	9.1%	10.4%
EBITDA Growth	502.2%	-50.0%	169.5%	30.3%	28.8%
Depn. & Amort.	306	450	509	591	669
EBIT	1,065	235	1,338	1,815	2,432
Other Income	497	787	858	1,021	1,225
Finance Cost	90	126	133	136	139
PBT before Excep. & Forex	1,471	896	2,063	2,700	3,518
Excep. & Forex Inc./Loss(-)	0	0	0	0	0
PBT	1,471	896	2,063	2,700	3,518
Taxes	366	169	522	683	890
Extraordinary Inc./Loss(-)	0	0	0	0	0
Assoc. Profit/Min. Int.(-)	-12	0	0	0	0
Reported Net Profit	1,118	727	1,541	2,017	2,628
Adjusted Net Profit	1,118	727	1,541	2,017	2,628
Net Margin	5.8%	3.5%	6.6%	7.7%	8.8%
Diluted Share Cap. (mn)	324.2	325.2	325.2	325.2	325.2
Diluted EPS (INR)	3.4	2.2	4.7	6.2	8.1
Diluted EPS Growth	295.3%	-35.2%	112.0%	30.9%	30.3%
Total Dividend + Tax	0	0	462	807	1,314
Dividend Per Share (INR)	0.0	0.0	1.4	2.5	4.0

Source: Company, JM Financial									
Cash Flow Statement					(INR mn)				
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E				
Profit before Tax	1,471	896	2,063	2,700	3,518				
Depn. & Amort.	306	450	509	591	669				
Net Interest Exp. / Inc. (-)	-407	-661	-725	-885	-1,086				
Inc (-) / Dec in WCap.	1,025	-53	-108	247	76				
Others	282	340	0	0	0				
Taxes Paid	-324	49	-225	-610	-751				
Operating Cash Flow	2,353	1,022	1,514	2,043	2,425				
Capex	-118	-199	-557	-526	-598				
Free Cash Flow	2,235	823	957	1,517	1,827				
Inc (-) / Dec in Investments	-4,482	-1,645	0	0	0				
Others	-99	393	858	1,021	1,225				
Investing Cash Flow	-4,698	-1,451	301	494	627				
Inc / Dec (-) in Capital	3,633	48	19	21	23				
Dividend + Tax thereon	0	0	-462	-807	-1,314				
Inc / Dec (-) in Loans	0	0	0	0	0				
Others	-265	-359	-125	-128	-130				
Financing Cash Flow	3,369	-311	-568	-913	-1,421				
Inc / Dec (-) in Cash	1,024	-741	1,247	1,624	1,631				
Opening Cash Balance	3,833	4,053	3,313	4,560	6,184				
Closing Cash Balance	4,857	3,313	4,560	6,184	7,815				

Source: Company, JM Financial

Balance Sheet					(INR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Shareholders' Fund	10,953	11,798	12,896	14,128	15,465
Share Capital	3,242	3,252	3,252	3,252	3,252
Reserves & Surplus	7,710	8,546	9,644	10,876	12,213
Preference Share Capital	0	0	0	0	0
Minority Interest	0	0	0	0	0
Total Loans	0	0	0	0	0
Def. Tax Liab. / Assets (-)	13	-95	-95	-95	-95
Total - Equity & Liab.	10,966	11,703	12,801	14,032	15,370
Net Fixed Assets	1,682	1,659	1,699	1,626	1,547
Gross Fixed Assets	1,593	1,767	2,324	2,851	3,449
Intangible Assets	528	528	528	528	528
Less: Depn. & Amort.	376	483	993	1,584	2,253
Capital WIP	-62	-153	-160	-169	-177
Investments	2,918	3,048	3,048	3,048	3,048
Current Assets	10,393	11,736	13,413	15,341	17,526
Inventories	1,228	1,583	1,654	1,802	1,966
Sundry Debtors	1,594	1,323	1,487	1,685	1,914
Cash & Bank Balances	4,857	3,313	4,560	6,184	7,815
Loans & Advances	2,410	5,176	5,341	5,263	5,383
Other Current Assets	304	341	371	408	448
Current Liab. & Prov.	4,027	4,739	5,359	5,983	6,751
Current Liabilities	3,841	4,171	4,461	4,990	5,594
Provisions & Others	186	568	898	993	1,157
Net Current Assets	6,366	6,997	8,054	9,359	10,775
Total – Assets	10,966	11,703	12,801	14,032	15,370

Source: Company, JM Financial

<b>Dupont Analysis</b>					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Margin	5.8%	3.5%	6.6%	7.7%	8.8%
Asset Turnover (x)	2.2	1.8	1.8	1.9	1.9
Leverage Factor (x)	1.0	1.0	1.0	1.0	1.0
RoE	13.1%	6.4%	12.5%	14.9%	17.8%
Key Ratios					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
BV/Share (INR)	33.8	36.3	39.7	43.4	47.6
ROIC	26.7%	4.4%	18.6%	26.6%	38.2%
ROE	13.1%	6.4%	12.5%	14.9%	17.8%
Net Debt/Equity (x)	-0.7	-0.5	-0.6	-0.7	-0.7
P/E (x)	81.8	126.2	59.5	45.5	34.9
P/B (x)	8.3	7.8	7.1	6.5	5.9
EV/EBITDA (x)	61.2	124.4	45.5	34.3	26.1
EV/Sales (x)	4.4	4.1	3.6	3.1	2.7
Debtor days	30	23	23	23	23
Inventory days	23	28	26	25	24
Creditor days	79	76	76	76	76

Source: Company, JM Financial

History of Re	commendation and	l Target Price	
Date	Recommendation	Target Price	% Chg.
15-Dec-23	Buy	515	
10-Feb-24	Buy	515	0.0
24-May-24	Buy	505	-1.9
9-Aug-24	Buy	505	0.0
23-Sep-24	Buy	530	5.0
15-Nov-24	Buy	410	-22.6
12-Feb-25	Buy	285	-30.5
4-Apr-25	Buy	280	-1.8
23-May-25	Buy	300	7.1
4-Jul-25	Buy	300	0.0
12-Aug-25	Buy	310	3.3
17-Aug-25	Buy	310	0.0
8-Oct-25	Add	325	4.8

# Recommendation History



## APPENDIX I

# JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.com

Compliance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: ashley.johnson@jmfl.com Grievance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: instcompliance@jmfl.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

New Rating System: Definition of ratings		
Rating	Meaning	
BUY	Expected return >= 15% over the next twelve months.	
ADD	Expected return >= 5% and < 15% over the next twelve months.	
REDUCE	Expected return >= -10% and < 5% over the next twelve months.	
SELL	Expected return < -10% over the next twelve months.	

Note: For REITs (Real Estate Investment Trust) and InvIT (Infrastructure Investment Trust) total expected returns include dividends or DPU (distribution per unit)

Previous Rating System: Definition of ratings				
Rating	Meaning			
BUY	Total expected returns of more than 10% for stocks with market capitalisation in excess of INR 200 billion and REITs* and more than 15%			
	for all other stocks, over the next twelve months. Total expected return includes dividend yields.			
	Price expected to move in the range of 10% downside to 10% upside from the current market price for stocks with market			
HOLD	capitalisation in excess of INR 200 billion and REITs* and in the range of 10% downside to 15% upside from the current market price			
	for all other stocks, over the next twelve months.			
SELL	Price expected to move downwards by more than 10% from the current market price over the next twelve months.			

<sup>\*</sup> REITs refers to Real Estate Investment Trusts.

#### Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

#### **Important Disclosures**

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions. Please click here to access our detailed Terms and Conditions, including the Most Important Terms and Conditions.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., JM Financial Institutional Securities has an affiliate, JM Financial Securities, Inc. located at 1325 Avenue of the Americas, 27th Floor, Office No. 2715, New York, New York 10019. Telephone +1 (332) 900 4958 which is registered with the SEC and is a member of FINRA and SIPC.

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions and a "permitted client" as such term is defined herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.